Related Experiment Video

Updated: Oct 23, 2026

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians
06:49

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians

Published on: March 14, 2014

Lipid-based amphotericin B for the treatment of fungal infections

D Slain1

  • 1Department of Pharmacy, Virginia Commonwealth University, Richmond 23298-0533, USA.

Pharmacotherapy
|April 30, 1999
PubMed

Insights

Lipid formulations of amphotericin B reduce kidney toxicity in fungal infections. However, due to limited efficacy data, they are recommended as second-line treatments for patients intolerant to conventional amphotericin B.

Area of Science:

  • Mycology
  • Infectious Diseases
  • Pharmacology

Background:

  • Life-threatening fungal infections are increasing.
  • Amphotericin B is the standard treatment but causes significant adverse events like nephrotoxicity.
  • Lipid-based amphotericin B formulations were developed to mitigate side effects.

Purpose of the Study:

  • To evaluate the clinical significance of differences among lipid-based amphotericin B formulations.
  • To assess the safety and efficacy of these formulations compared to conventional amphotericin B.

Main Methods:

  • Review of available clinical data on lipid-based amphotericin B formulations.
  • Comparison of adverse event profiles, particularly nephrotoxicity.
  • Assessment of efficacy data for systemic and deep-seated fungal infections.

Main Results:

  • Lipid formulations appear to have a reduced propensity for causing nephrotoxicity.
  • Clinical data on the efficacy of these formulations are limited.
  • Differences in composition and pharmacokinetics among formulations are not fully understood in terms of clinical significance.

Conclusions:

  • Lipid-based amphotericin B formulations show promise in reducing nephrotoxicity.
  • Due to limited efficacy data, these formulations should be reserved for specific patient populations.
  • Consideration as second-line therapy for patients failing or intolerant to conventional amphotericin B or other antifungals is recommended.

Related Concept Videos

Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Candidiasis01:20

Candidiasis

Candidiasis is a fungal infection caused by opportunistic species of Candida. It can affect various anatomical sites, including the skin, oral cavity, nails, and genitourinary tract. Among its forms, vaginal candidiasis is the most common type of mucosal infection. It typically results from the overgrowth of Candida albicans in the vaginal mucosa. Under normal conditions, C. albicans exists as a commensal organism within the vaginal microbiota, regulated by the dominance of lactobacilli, which...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
Fungal Phylum Microsporidia01:28

Fungal Phylum Microsporidia

Microsporidia are a group of obligate intracellular fungi that were initially classified as protists but were later reclassified based on phylogenetic, molecular, and structural evidence linking them to the Chytridiomycota. These unicellular, non-motile organisms are highly specialized parasites that infect a wide range of animal hosts, including humans. They have evolved extensive genomic and metabolic reductions, making them highly dependent on their hosts for survival.Morphology and Genomic...
Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...